55.22
price down icon0.47%   -0.26
after-market 시간 외 거래: 55.22
loading
전일 마감가:
$55.48
열려 있는:
$55.12
하루 거래량:
441.53K
Relative Volume:
0.50
시가총액:
$3.42B
수익:
$45.48M
순이익/손실:
$169.95M
주가수익비율:
21.08
EPS:
2.62
순현금흐름:
$230.85M
1주 성능:
-0.02%
1개월 성능:
+3.52%
6개월 성능:
+44.93%
1년 성능:
+55.33%
1일 변동 폭
Value
$54.59
$55.63
1주일 범위
Value
$54.54
$57.73
52주 변동 폭
Value
$32.50
$60.60

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Name
명칭
Protagonist Therapeutics Inc
Name
전화
(510) 474-0170
Name
주소
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Name
직원
124
Name
트위터
Name
다음 수익 날짜
2025-05-02
Name
최신 SEC 제출 서류
Name
PTGX's Discussions on Twitter

PTGX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
PTGX
Protagonist Therapeutics Inc
55.22 3.42B 45.48M 169.95M 230.85M 2.62
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-06-17 개시 Citigroup Buy
2024-12-06 개시 BMO Capital Markets Outperform
2024-12-06 개시 Goldman Neutral
2024-11-05 개시 Wedbush Outperform
2024-09-24 개시 TD Cowen Buy
2024-09-09 개시 Truist Buy
2023-10-30 개시 CapitalOne Overweight
2023-05-25 재개 Jefferies Buy
2022-08-25 개시 JMP Securities Mkt Outperform
2022-02-11 개시 BTIG Research Buy
2021-10-12 업그레이드 JP Morgan Neutral → Overweight
2021-10-11 업그레이드 Northland Capital Market Perform → Outperform
2021-09-20 다운그레이드 JP Morgan Overweight → Neutral
2021-05-24 개시 JMP Securities Mkt Outperform
2021-05-24 개시 Northland Capital Outperform
2021-01-06 개시 JP Morgan Overweight
2020-12-16 개시 Piper Sandler Overweight
2020-09-18 재확인 H.C. Wainwright Buy
2020-07-15 개시 Jefferies Buy
2020-05-18 재확인 H.C. Wainwright Buy
2019-07-08 개시 H.C. Wainwright Buy
2019-05-09 업그레이드 Stifel Hold → Buy
2018-12-06 개시 Nomura Buy
2018-01-29 개시 Stifel Buy
2017-07-21 개시 BTIG Research Buy
모두보기

Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스

pulisher
04:26 AM

Polycythemia Vera Pipeline 2025: Latest FDA Approvals, - openPR.com

04:26 AM
pulisher
12:02 PM

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis - The Des Moines Register

12:02 PM
pulisher
08:16 AM

Protagonist Announces Submission of NDA for First Icotrokinra U. - GuruFocus

08:16 AM
pulisher
Jul 20, 2025

Is Protagonist Therapeutics Inc. a good long term investmentExceptional profit margins - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about Protagonist Therapeutics Inc. stockFree Real-Time Stock Data - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 20, 2025

What drives Protagonist Therapeutics Inc. stock priceUnmatched profit growth - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 17, 2025

How the (PTGX) price action is used to our Advantage - news.stocktradersdaily.com

Jul 17, 2025
pulisher
Jul 15, 2025

How Protagonist Therapeutics Inc. stock performs during market volatilityLow Risk Stock Strategies - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Protagonist Therapeutics Inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Protagonist Therapeutics Inc. stock price move sharplyReal Time Stock Signal - Newser

Jul 15, 2025
pulisher
Jul 12, 2025

Insiders At Protagonist Therapeutics Sold US$5.1m In Stock, Alluding To Potential Weakness - 富途牛牛

Jul 12, 2025
pulisher
Jul 02, 2025

Protagonist selects GLP-1/GIP/GCG receptor agonist peptide for obesity - BioWorld MedTech

Jul 02, 2025
pulisher
Jun 30, 2025

Transcript : Protagonist Therapeutics, Inc.Special Call - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity - The Oklahoman

Jun 30, 2025
pulisher
Jun 26, 2025

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Lubbock Avalanche-Journal

Jun 26, 2025
pulisher
Jun 26, 2025

Protagonist Therapeutics to Host Conference Call to Announce an - GuruFocus

Jun 26, 2025
pulisher
Jun 24, 2025

Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera - Yahoo Finance

Jun 24, 2025
pulisher
Jun 20, 2025

Protagonist Therapeutics: Two 'Slam Dunk' Sets Of Pivotal Data Set Up Bull Case (PTGX) - Seeking Alpha

Jun 20, 2025
pulisher
Jun 18, 2025

10 Biotech Stocks Screaming a Buy - Insider Monkey

Jun 18, 2025
pulisher
Jun 18, 2025

Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth By Investing.com - Investing.com South Africa

Jun 18, 2025
pulisher
Jun 18, 2025

Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth - Investing.com

Jun 18, 2025
pulisher
Jun 17, 2025

BIOTECHNOLOGY VALUE FUND L P's Strategic Acquisition in Protagonist Therapeutics Inc - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Citigroup Initiates Coverage on Protagonist Therapeutics (PTGX) with a 'Buy' Rating | PTGX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $7 - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $72 Target | PTGX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Citi initiates Protagonist Therapeutics stock with buy rating on drug potential - Investing.com Nigeria

Jun 17, 2025
pulisher
Jun 16, 2025

How To Trade (PTGX) - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 16, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

GAMMA Investing LLC Raises Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Jun 16, 2025
pulisher
Jun 14, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Sells $570,300.00 in Stock - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com Canada

Jun 14, 2025
pulisher
Jun 14, 2025

Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

Subdued Growth No Barrier To Protagonist Therapeutics, Inc. (NASDAQ:PTGX) With Shares Advancing 27% - simplywall.st

Jun 13, 2025
pulisher
Jun 11, 2025

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 - The Columbus Dispatch

Jun 11, 2025
pulisher
Jun 11, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Rating Increased to Hold at Wall Street Zen - MarketBeat

Jun 11, 2025
pulisher
Jun 10, 2025

Hennion & Walsh Asset Management Inc. Has $1.26 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Jun 10, 2025
pulisher
Jun 09, 2025

California State Teachers Retirement System Sells 316 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Upgraded to “Hold” at Wall Street Zen - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Protagonist Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:PTGX - Benzinga

Jun 06, 2025
pulisher
Jun 05, 2025

Exploring Three High Growth Tech Stocks In The US Market - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

(PTGX) Long Term Investment Analysis - news.stocktradersdaily.com

Jun 04, 2025
pulisher
Jun 04, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Cut to "Sell" at Wall Street Zen - MarketBeat

Jun 04, 2025
pulisher
Jun 04, 2025

Protagonist Therapeutics’ (PTGX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Protagonist-Takeda, Novartis post phase III wins - BioWorld MedTech

Jun 03, 2025
pulisher
Jun 03, 2025

H.C. Wainwright reaffirms Buy rating on Protagonist Therapeutics stock By Investing.com - Investing.com UK

Jun 03, 2025
pulisher
Jun 03, 2025

BTIG maintains buy rating on Protagonist Therapeutics stock By Investing.com - Investing.com UK

Jun 03, 2025
pulisher
Jun 03, 2025

Protagonist Therapeutics (PTGX) Rating and Price Target Reaffirmed | PTGX Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $66 - 富途牛牛

Jun 03, 2025

Protagonist Therapeutics Inc (PTGX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
자본화:     |  볼륨(24시간):